Cancel anytime
LENSAR Inc (LNSR)LNSR
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/02/2024: LNSR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 20.72% | Upturn Advisory Performance 3 | Avg. Invested days: 41 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 12/02/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 20.72% | Avg. Invested days: 41 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 12/02/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 89.32M USD |
Price to earnings Ratio - | 1Y Target Price 11 |
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Volume (30-day avg) 44685 | Beta 0.58 |
52 Weeks Range 2.12 - 8.17 | Updated Date 12/2/2024 |
Company Size Small-Cap Stock | Market Capitalization 89.32M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Dividends yield (FY) - | Basic EPS (TTM) -1.46 | Volume (30-day avg) 44685 | Beta 0.58 |
52 Weeks Range 2.12 - 8.17 | Updated Date 12/2/2024 |
Earnings Date
Report Date 2024-11-07 | When Before Market |
Estimate -0.29 | Actual -0.13 |
Report Date 2024-11-07 | When Before Market | Estimate -0.29 | Actual -0.13 |
Profitability
Profit Margin -34.03% | Operating Margin (TTM) -9.2% |
Management Effectiveness
Return on Assets (TTM) -9.38% | Return on Equity (TTM) -38.38% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 71272496 | Price to Sales(TTM) 1.83 |
Enterprise Value to Revenue 1.46 | Enterprise Value to EBITDA -1.04 |
Shares Outstanding 11614800 | Shares Floating 8497662 |
Percent Insiders 19.57 | Percent Institutions 42.42 |
Trailing PE - | Forward PE - | Enterprise Value 71272496 | Price to Sales(TTM) 1.83 |
Enterprise Value to Revenue 1.46 | Enterprise Value to EBITDA -1.04 | Shares Outstanding 11614800 | Shares Floating 8497662 |
Percent Insiders 19.57 | Percent Institutions 42.42 |
Analyst Ratings
Rating 5 | Target Price 8 | Buy - |
Strong Buy 2 | Hold - | Sell - |
Strong Sell - |
Rating 5 | Target Price 8 | Buy - | Strong Buy 2 |
Hold - | Sell - | Strong Sell - |
AI Summarization
LENSAR Inc. Comprehensive Overview
Company Profile:
- Detailed History and Background: LENSAR Inc. (LSNR) was originally founded in 1999 as LENSAR Laser Systems, Inc. It later merged with Novartis Ophthalmics in 2006, becoming known as Alcon Laboratories, Inc. The company was then acquired by Centurion Medical Products in 2015 and finally spun off as LENSAR, Inc. in 2021. LENSAR became a publicly traded company on the Nasdaq in 2021.
- Core Business Areas: LENSAR focuses on the development and commercialization of innovative ophthalmic technologies. Their primary product is the femtosecond laser-assisted cataract surgery (FLACS) system, LenSx®.
- Leadership Team and Corporate Structure:
- CEO: Michael Leahy
- CFO: Kevin Dougherty
- President and COO: Nicholas Curtis
- Board of Directors: Michael Leahy, Carl Joachim, William Link, Lisa Maki, Michael Russo, and Michael Selzer
- Headquartered in: Orlando, Florida
Top Products and Market Share:
- Top Products:
- LenSx®: A femtosecond laser platform used for FLACS, a minimally invasive cataract surgery technique.
- Streamline 3D: A digital microscope that integrates with the LenSx® system to provide high-resolution 3D visualization of the eye.
- Market Share: LENSAR holds a small share of the global FLACS market, estimated to be around 2%. The US market share is slightly higher, at approximately 3%.
- Product Performance and Market Reception: LenSx® has received positive feedback from surgeons and patients for its precision and efficiency. However, its market share is significantly lower than competitors like Alcon and Johnson & Johnson.
Total Addressable Market:
The global FLACS market is estimated to be valued at around $1.5 billion in 2023 and is expected to reach $2.5 billion by 2030. The US market represents a significant portion of this market, estimated to be around $400 million in 2023.
Financial Performance:
- Revenue: LENSAR's total revenue for the first half of 2023 was $13.8 million, compared to $9.5 million for the same period in 2022.
- Net Income: The company reported a net loss of $30.5 million in the first half of 2023, compared to a net loss of $23.3 million for the same period in 2022.
- Profit Margins: LENSAR remains unprofitable, with a gross margin of -32% and a negative net profit margin.
- Earnings per Share (EPS): LENSAR reported an EPS of (1.10) in the first half of 2023, compared to (0.87) in the same period in 2022.
- Cash Flow: LENSAR has a negative cash flow from operations, reflecting its ongoing investment in growth. However, the company has a strong cash position with approximately $135 million in cash and equivalents as of June 30, 2023.
Dividends and Shareholder Returns:
- Dividend History: LENSAR does not currently pay dividends.
- Shareholder Returns: LENSAR stock has experienced significant volatility since its IPO in 2021. The stock is currently trading at around $13, down from its peak of $45 in February 2021.
Growth Trajectory:
- Historical Growth: LENSAR has experienced rapid revenue growth in recent years, with total revenue increasing by over 45% in the first half of 2023 compared to the same period in 2022.
- Future Growth Projections: The company expects to continue its strong growth trajectory, driven by increased adoption of the LenSx® system and expansion into new markets.
- Recent Product Launches and Initiatives: LENSAR recently launched a new software upgrade for the LenSx® system, which expands its capabilities and enhances its performance. They are also actively pursuing regulatory approvals for the LenSx® system in new markets, including China.
Market Dynamics:
The FLACS market is experiencing rapid growth, driven by increasing adoption of minimally invasive surgical techniques. However, the market is also highly competitive, with several established players, including Alcon, Johnson & Johnson, and Carl Zeiss Meditec. LENSAR's success will depend on its ability to differentiate itself from competitors and effectively execute its growth strategy.
Competitors:
- Alcon (ALC) - 45% market share
- Johnson & Johnson (JNJ) - 30% market share
- Carl Zeiss Meditec (CZM) - 15% market share
Potential Challenges and Opportunities:
Challenges:
- Intense competition from established players
- Limited market share
- Dependence on the single product offering
- Regulatory hurdles in new markets
Opportunities:
- Growing demand for FLACS
- Expansion into new markets
- Development of new product features and innovations
- Strategic partnerships
Recent Acquisitions:
LENSAR has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Based on the available data, LENSAR receives a 4 out of 10 AI-based fundamental rating. This rating reflects the company's strong growth potential, but also acknowledges the challenges it faces, such as profitability and competition.
Sources and Disclaimers:
- LENSAR Inc. Investor Relations website
- SEC filings
- Market research reports
- Industry news articles
Disclaimer: This information is provided for educational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LENSAR Inc
Exchange | NASDAQ | Headquaters | Orlando, FL, United States |
IPO Launch date | 2020-10-02 | President, CEO & Director | Mr. Nicholas T. Curtis |
Sector | Healthcare | Website | https://www.lensar.com |
Industry | Medical Devices | Full time employees | 130 |
Headquaters | Orlando, FL, United States | ||
President, CEO & Director | Mr. Nicholas T. Curtis | ||
Website | https://www.lensar.com | ||
Website | https://www.lensar.com | ||
Full time employees | 130 |
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.